Adavivint

Research use only, not for human use.

Adavivint (SM-04690, SM 04690, SM04690) is a novel small molecule Wnt pathway inhibitor with EC50 of 3 nM in vitro.

Adavivint (SM-04690, SM 04690, SM04690) is a novel small molecule Wnt pathway inhibitor with EC50 of 3 nM in vitro; induces hMSC differentiation into mature, functional chondrocytes and decreases cartilage catabolic marker levels; significantly improves Osteoarthritis Research Society International (OARSI) histology scores and biomarkers in a rodent OA model.Rheumatoid Arthritis Phase 2 Clinical(In Vitro):Adavivint (SM04690) is a potent and selective inhibitor of Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells, and shows no effect on SV40 luciferase reporter. Adavivint enhances aggregation of human mesenchymal stem cells (hMSCs) with an EC50 of 10 nM. Adavivint (30 nM) protects chondrocytes from catabolic breakdown in vitro.(In Vivo):Adavivint (0.3 μg) enhances cartilage repair and protection in the rat acute cruciate ligament tear and partial medial meniscectomy osteoarthritis (ACLT + pMMx OA) model.

——

——

SM-04690 | SM 04690 | SM04690

Wnt/Notch/Hedgehog

Wnt/beta/catenin

Wnt/beta/catenin

Inflammation/Immunology

Rheumatoid Arthritis

1467093-03-3

505.557

C29H24FN7O

>98% (HPLC)

DMSO : 25 mg/mL 49.45 mM

CC(C)CC(=O)NC1=CN=CC(=C1)C2=CC3=C(C=C2)NN=C3C4=NC5=C(N4)C=NC=C5C6=CC(=CC=C6)F

N-(5-{3-[7-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-5-yl}pyridin-3-yl)-3-methylbutanamide

(-20℃)

With Ice Pack

≥ 2 years